Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Kathleen Colson"'
Autor:
Jacalyn Rosenblatt, Diane Warren, Kelly Masone, Dena Grayson, Sascha A. Tuchman, Kathleen Colson, Paul G. Richardson, Jacob P. Laubach, Robert A. Redd, Constantine S. Mitsiades
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age: 63 years [range: 50–77]) and a med
Publikováno v:
Clinical journal of oncology nursing. 25(6)
Background Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior therapies. Because isatuximab is a
Autor:
Ofer Shpilberg, Irene M. Ghobrial, Moshe Mittelman, Ashraf Badros, Ivan Spicka, Arnon Nagler, Kenneth C. Anderson, Richard Leblanc, Jacob P. Laubach, Kihyun Kim, Teru Hideshima, Peter Sportelli, Paul Blake, Paul G. Richardson, Moshe E. Gatt, Merav Leiba, Sung-Soo Yoon, Michael Chen, Kathleen Colson, Roman Hájek, Hakan Kaya, Joaquin Martinez-Lopez, Parameswaran Hari, Dina Ben-Yehuda
Publikováno v:
EJHaem. 1(1)
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouraging early-p
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
Constantine S. Mitsiades, Mary McKenney, Teru Hideshima, Katherine Redman, Robert L. Schlossman, Paul G. Richardson, Kathleen Colson, Diane Warren, Irene M. Ghobrial, Laura E. Lunde, Nikhil C. Munshi, Kimberly Noonan, Deborah Doss, Kenneth C. Anderson, Jacob P. Laubach
Publikováno v:
European Journal of Haematology. 88:446-449
We present the case of a woman with relapsed multiple myeloma (MM) who received combination lenalidomide and bortezomib therapy for 90 cycles followed by continuous lenalidomide monotherapy and has completed over 100 cycles of treatment to date. The
Autor:
L. Gardner, Amrita Krishnan, Robert L. Schlossman, Jeff Allerton, Jacob P. Laubach, David Irwin, Sagar Lonial, Kathleen Colson, John J. Densmore, Noopur Raje, Peter Sportelli, Jeff Zonder, Enrique Poradosu, Jeff Wolf, Andrzej Jakubowiak, Kenneth C. Anderson, Michael Bar, Paul G. Richardson, Irene M. Ghobrial, Teru Hideshima, Thomas Martin, Nikhil C. Munshi
Publikováno v:
Journal of Clinical Oncology. 29:4243-4249
Purpose Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator, perifosine, enhances the cytotoxicity of dexamethasone and bortezomib. Cl
Autor:
Edie Weller, Jacob P. Laubach, Paul G. Richardson, Robert A. Redd, Ashley Motta, Sascha A. Tuchman, Kathleen Colson, Kathleen Fitzpatrick, Jacalyn Rosenblatt
Publikováno v:
Journal of Clinical Oncology. 34:8014-8014
8014Background: Panobinostat (pano), a potent inhibitor of histone deacetylases (HDACs), is approved for use in combination with bortezomib (bortez) and dexamethasone (dex) in relapsed and refracto...
Publikováno v:
Cancer nursing. 31(3)
Multiple myeloma is the second most common hematologic malignancy and remains incurable, despite advances in chemotherapy and stem cell transplantation. Bortezomib, a novel proteasome inhibitor, is approved for the treatment of patients with multiple
Autor:
Monica Mitchell, Jonathan L. Kaufman, Paul G. Richardson, L. Gardner, Teru Hideshima, Melissa Alsina, Kathleen Colson, Kenneth C. Anderson, Peter Sportelli, Todd M. Zimmerman, Kathy Giusti, Andrzej Jakubowiak, Colleen K. Harvey, Malathi Kandarpa
Publikováno v:
Blood. 116:3064-3064
Abstract 3064 Introduction: Perifosine (Peri) a novel, oral signal transduction modulator with multiple effects including inhibition of Akt and activation of JNK, has demonstrated clinical activity when combined with dexamethasone (Dex) in patients (
Autor:
John J. Densmore, Andrzej Jakubowiak, Robert Birch, Aparna Krishnan, Peter Sportelli, I. C. Henderson, Irene M. Ghobrial, Tara Kendall, L. Gardner, Jeffrey L. Wolf, Kathleen Colson, Seema Singhal, J. Stephenson, J. F. Martin, Dixil Francis, L. Lai, Teru Hideshima, N. Obadike, KC Anderson, Paul G. Richardson, Jayesh Mehta, Kevin Sullivan, Sagar Lonial
Publikováno v:
Blood. 110:1164-1164
INTRODUCTION: Perifosine (peri) is an oral, novel synthetic alkylphospholipid, with multiple effects on signal transduction pathways, including inhibition of Akt and activation of JNK. In vitro studies showed that peri induces cytotoxicity in both MM